Marzena

Mersana Therapeutics is a clinical-stage biopharmaceutical company focused on developing a pipeline of novel antibody-drug conjugates (ADCs) for the treatment of various cancers. The company utilizes its proprietary platforms, including Dolasynthen and Immunosynthen, to create ADCs with optimized drug-to-antibody ratios and improved therapeutic indices. While its lead candidate, upifitamab rilsodotin (UpRi), recently faced clinical setbacks in ovarian cancer, Mersana continues to advance its earlier-stage pipeline, including XMT-1660 and XMT-2056. The company maintains strategic partnerships with major pharmaceutical firms such as GSK, Merck KGaA, and Janssen to leverage its ADC technology. Mersana is headquartered in Cambridge, Massachusetts, and is publicly traded on the NASDAQ exchange.